Apogee Therapeutics (APGE) Expected to Announce Quarterly Earnings on Tuesday

Apogee Therapeutics (NASDAQ:APGE) is expected to announce its Q3 2025 results before the market opens on Tuesday, November 11th. Analysts expect the company to announce earnings of ($1.14) per share for the quarter. Parties may review the information on the company’s upcoming Q3 2025 earningreport for the latest details on the call scheduled for Wednesday, November 19, 2025 at 12:30 PM ET.

Apogee Therapeutics (NASDAQ:APGE) last posted its quarterly earnings data on Monday, August 11th. The company reported ($1.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.03) by ($0.10). On average, analysts expect Apogee Therapeutics to post $-3 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Apogee Therapeutics Stock Down 0.5%

Shares of NASDAQ:APGE opened at $54.71 on Monday. The company has a market cap of $2.52 billion, a P/E ratio of -13.25 and a beta of 1.50. The business has a fifty day simple moving average of $45.64 and a 200-day simple moving average of $41.45. Apogee Therapeutics has a 52 week low of $26.20 and a 52 week high of $63.50.

Insider Transactions at Apogee Therapeutics

In related news, insider Carl Dambkowski sold 10,785 shares of the stock in a transaction that occurred on Wednesday, November 5th. The shares were sold at an average price of $55.07, for a total transaction of $593,929.95. Following the completion of the sale, the insider owned 282,008 shares of the company’s stock, valued at approximately $15,530,180.56. This represents a 3.68% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last three months, insiders have sold 18,620 shares of company stock worth $900,504. 42.77% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Apogee Therapeutics

Several institutional investors have recently bought and sold shares of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of Apogee Therapeutics by 2.9% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 24,529 shares of the company’s stock worth $921,000 after acquiring an additional 694 shares in the last quarter. BNP Paribas Financial Markets boosted its position in Apogee Therapeutics by 34.7% during the 2nd quarter. BNP Paribas Financial Markets now owns 3,649 shares of the company’s stock worth $158,000 after purchasing an additional 941 shares during the period. Legal & General Group Plc boosted its position in Apogee Therapeutics by 7.4% during the 2nd quarter. Legal & General Group Plc now owns 27,689 shares of the company’s stock worth $1,203,000 after purchasing an additional 1,907 shares during the period. Invesco Ltd. increased its holdings in Apogee Therapeutics by 10.5% in the 2nd quarter. Invesco Ltd. now owns 26,866 shares of the company’s stock valued at $1,167,000 after purchasing an additional 2,556 shares in the last quarter. Finally, E Fund Management Co. Ltd. purchased a new position in Apogee Therapeutics in the second quarter valued at about $204,000. 79.04% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

APGE has been the subject of several recent analyst reports. Wedbush restated an “outperform” rating and issued a $90.00 price target on shares of Apogee Therapeutics in a report on Monday, August 11th. BTIG Research reissued a “buy” rating and issued a $115.00 target price on shares of Apogee Therapeutics in a research report on Thursday, October 9th. Zacks Research downgraded shares of Apogee Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, August 14th. Craig Hallum assumed coverage on shares of Apogee Therapeutics in a research note on Monday, November 3rd. They set a “buy” rating and a $109.00 price target on the stock. Finally, Mizuho assumed coverage on shares of Apogee Therapeutics in a report on Tuesday, October 21st. They issued an “outperform” rating and a $105.00 price target on the stock. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $96.50.

Apogee Therapeutics Company Profile

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.